Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Walgreens Boots Alliance Q3 profits beat expectations

(Sharecast News) - Drugstore chain Walgreens Boots Alliance reported Q3 profits that came in ahead of Wall Street expectations. Walgreens said adjusted earnings per share came to $0.38 in the three months ended 31 May, above analyst estimates of $0.31 but down from $0.63 a year ago, primarily due to a higher adjusted effective tax rate, increased incentive accruals, lower US retail sales and lower equity earnings in its Cencora unit, partly offset by cost savings within its US retail pharmacy division.

Revenues grew 7.2% to $39.0bn, beating expectations of $36.8bn.

Walgreens also noted that, given its pending sale to Sycamore Partners, it has withdrawn its fiscal 2025 guidance.

Chief executive Tim Wentworth said: "Third quarter results reflect continued improvement in our US healthcare segment and benefits from our cost savings initiatives, while we continued to see weakness in our US front-end sales.

"We remain focused on our turnaround plan, which will require time, disciplined focus and a balanced approach to manage future cash needs with investments necessary to navigate an evolving pharmacy and retail environment."

As of 1400 BST, Walgreens shares were down 0.62% in pre-market trading at $11.38 each.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.